Skip to main content
IRLAB Therapeutics logo

IRLAB Therapeutics — Investor Relations & Filings

Ticker · IRLAB ISIN · SE0012675361 LEI · 549300JAT34LHEI0DH60 ST Manufacturing
Open in API
Filings indexed 157 across all filing types
Latest filing 2022-05-11 AGM Information
Country SE Sweden
Listing ST IRLAB

About IRLAB Therapeutics

https://irlab.se/

IRLAB Therapeutics is a research and development company that discovers and develops novel treatments for neurodegenerative diseases, with a primary focus on Parkinson's disease and other central nervous system (CNS) disorders. The company's research originates from Nobel Prize-winning science and is driven by its proprietary Integrative Screening Process (ISP) platform. This systems pharmacology-based discovery engine utilizes an extensive database to generate a pipeline of drug candidates. The company's portfolio includes clinical-stage assets such as Mesdopetam (IRL790), in development for treating levodopa-induced dyskinesia (LIDs), and Pirepemat (IRL752), which is being developed to reduce falls and improve balance in patients with Parkinson's disease.

Recent filings

Filing Released Lang Actions
Kommuniké från årsstämma 2022 i IRLAB Therapeutics AB
AGM Information Classification · 99% confidence The document is explicitly titled "Kommuniké från årsstämma 2022 i IRLAB Therapeutics AB" (Communiqué from the Annual General Meeting 2022 of IRLAB Therapeutics AB). It details the decisions made at the meeting, such as the disposition of results, granting of discharge to management, board elections, approval of remuneration reports and guidelines, and authorization for share issuance. These topics are central to an Annual General Meeting (AGM). Therefore, the correct classification is AGM-R (AGM Information). The document is a summary/communiqué of the meeting, not a proxy statement (PSI) or a general regulatory filing (RNS).
2022-05-11 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January–March 2022 for IRLAB. It contains comprehensive financial tables (income statement, balance sheet metrics), management commentary (CEO's letter), and detailed updates on the company's R&D pipeline and clinical trials. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2022
2022-05-11 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January – March 2022' and contains detailed financial tables (Net sales, Operating profit, etc.) for the specified period, alongside management commentary and project updates. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2022
2022-05-11 English
IRLAB acquires know-how connected to the P003 project aimed at an innovative treatment for Parkinson’s disease
Regulatory Filings Classification · 95% confidence The document is titled as a press release dated April 22, 2022, announcing a specific corporate action: the acquisition of know-how related to the P003 project and the subsequent issuance of new shares to complete the transaction. This involves a capital structure change (share issue) as consideration for an asset acquisition. While it touches upon financing (CAP) and M&A (TAR), the core announcement is a corporate action involving the issuance of shares, which aligns closely with 'Share Issue/Capital Change' (SHA). However, since this is a general corporate announcement released via a press release format, and it details a specific transaction rather than being a formal regulatory filing like a 10-K or a dedicated financing document, the most appropriate general category for non-standard, material corporate news that doesn't fit the highly specific categories (like DIV, DIRS, ER) is often the general 'Regulatory Filings' (RNS) or, if the focus is purely on the share issuance, SHA. Given the context of a press release announcing a material event (acquisition consideration paid via share issuance), and the presence of an attachment link suggesting this is the primary announcement, RNS (Regulatory Filings/General Announcement) is a strong candidate if SHA is too specific for a general press release format. Since the text explicitly details a directed share issue deviating from preemption rights, 'SHA' (Share Issue/Capital Change) is highly relevant. However, many such press releases are classified as RNS if they are not a specific SEC/exchange form. Given the content is a material corporate event announcement, and it is not a report itself (Rule 2 applies, but this is the announcement), RNS is the safest general classification for a press release of this nature, unless the primary focus is strictly the capital change. Since the document is a press release announcing a transaction involving share issuance, RNS is the best fit as a general regulatory announcement.
2022-04-22 English
IRLAB förvärvar know-how kopplad till P003-projektet som är inriktat mot innovativ behandling av Parkinsons sjukdom
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated April 22, 2022, announcing that IRLAB is acquiring know-how and patents related to its P003 project (Parkinson's treatment) from Per Lindberg Consulting AB. The announcement details the consideration (cash and newly issued shares via a directed share issue) and its impact on the share count. This type of announcement, detailing a specific corporate transaction (acquisition/financing component via share issuance), fits best under 'Capital/Financing Update' (CAP) or potentially 'Regulatory Filings' (RNS) if it were a general disclosure. However, since it explicitly details a financing/capital structure change (issuance of 120,000 new shares to fulfill an acquisition agreement), CAP is the most specific fit. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). Given the focus on the share issuance as part of the consideration, CAP is appropriate.
2022-04-22 Swedish
NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OF
AGM Information Classification · 99% confidence The document is explicitly titled "NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OF IRLAB THERAPEUTICS AB" and details the date, time, location, registration procedures, and the proposed agenda for the meeting. The agenda items cover the election of the chairman, approval of financial statements (items 8-11), election of directors and auditors (items 12-15), and resolutions on remuneration and share authorizations. This content is characteristic of the preparatory materials sent out before a general meeting, which aligns perfectly with the definition of AGM Information (AGM-R). It is not a full 10-K, an Earnings Release (ER), or a simple announcement of a report (RPA), but the notice and associated proposals for the AGM itself.
2022-04-11 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.